Product Description
| Brand |
Snibe |
| Sample Type |
Serum |
| Pack Size |
100T |
| CAT No. |
130201015M |
| Application |
Cancer Marker |
The kit has been designed for the quantitative determination of Cancer Antigen 72-4 (CA 72-4) in human serum. The method can be used for samples over the range of 2.0-500.0 U/ml. The test has to be performed on the Fully-auto chemiluminescence immunoassay (CLIA) analyzer MAGLUMI (Including Maglumi 600,Maglumi 1000,Maglumi 1000 Plus, Maglumi 2000,Maglumi 2000 Plus,Maglumi 3000 and Maglumi 4000).
Efficient and Accurate Tumor Marker DetectionThe Snibe MAGLUMI CA 72-4 (CLIA) kit offers laboratories a trusted solution for detecting and quantifying CA 72-4, a significant tumor marker in cancer diagnostics. The two-step chemiluminescent immunoassay ensures high sensitivity and specificity, while automation on MAGLUMI analyzers streamlines workflow and improves operational consistency. Its quantitative approach makes the kit suitable for both clinical diagnosis and patient monitoring.
User-Friendly and Ready-to-Use ReagentsAll reagents, calibrators, and controls in the kit are pre-prepared and ready for use, minimizing the risk of contamination and simplifying assay preparation. The included buffer and advanced magnetic microbead technology deliver reliable results with each batch. Guidelines for calibration, storage, and handling maximize assay performance and longevity.
FAQ's of Snibe MAGLUMI CA 72-4 (CLIA):
Q: How is the Snibe MAGLUMI CA 72-4 (CLIA) kit used in a clinical laboratory setting?
A: The kit is designed for automated, quantitative detection of CA 72-4 in human serum or plasma samples using MAGLUMI series analyzers. Lab staff simply load the reagents, calibrators, and samples into the analyzer, and the system handles the assay process and chemiluminescent detection.
Q: What sample types are compatible with the Snibe MAGLUMI CA 72-4 (CLIA) assay?
A: This assay accepts human serum or plasma samples collected using EDTA, heparin, or citrate as anticoagulants, making it adaptable to standard laboratory sample collection procedures.
Q: When should calibration be performed with this kit?
A: Calibration is recommended every four weeks, or more frequently if advised by specific analyzer protocols. This ensures that test results remain precise and consistent.
Q: Where should the kit be stored after opening, and how should it be handled?
A: After opening, store the kit components at 2-8C and avoid freeze-thaw cycles. Ensure all reagents are used within their shelf life (typically 12 months) and follow the manufacturer's guidelines for safe handling.
Q: What are the main benefits of using the Snibe MAGLUMI CA 72-4 (CLIA) kit?
A: Key benefits include high analytical sensitivity (0.5 U/mL), automation for efficient workflow, CE marking for regulatory assurance, and compatibility with widely used MAGLUMI analyzers. Laboratories can expect accurate, reliable results suitable for effective cancer marker screening and monitoring.
Q: How does the detection process work in this kit?
A: The CA 72-4 assay utilizes a two-step chemiluminescence immunoassay principle, employing magnetic microbeads and ABEI labels to achieve high sensitivity and specificity within approximately 29 minutes per analysis.